Sinclair Pharma Regulatory News (SPH)

Sinclair Pharma plc

Additional listing - Replacement

The following announcement replaces the one issued by Sinclair Pharma plc on 26 September 2016 with RNS number 8633K. The total number of new ordinary shares of 1p each for which application is being made is 4,674,735 and not 4,674,900.

London, 28 September 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that a total of 4,674,735 new ordinary shares of 1p each (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the Company's Value Creation Plan ("VCP") and the issue of shares under the Company's 2013 Bonus Plan ("Bonus Plan").

 1,577,835 New Ordinary Shares are being issued under the terms of the VCP and 3,096,900 New Ordinary Shares are being issued under the terms of the Bonus Plan. This includes 1,810,980 New Ordinary Shares agreed to be issued to Christophe Foucher, former COO of Sinclair, under the terms of his severance package announced on 1 September 2016.

Awards under the Bonus Plan include shares awarded to the following executive Directors:

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 30 September 2016 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares. Following admission of the New Ordinary Shares, Sinclair will have 502,089,508 ordinary shares of 1p in issue.

For further information please contact:

Media enquiries

Notes to Editors:

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com